Healthcare
No matter how we manage our health, efficacy, risks and costing are top concernsTumor necrosis factor blocker or inhibitor drugs causes Lymphoma
Tumor necrosis factor (TNF) blockers is drugs often used in patients with Chron’s disease, psoriasis, ankylosing spndylitis, rheumatoid arthritis, and asthma due to autoimmune disorders.
However, since the report of cancer in the lymphatic cells of the immune systemin teens, especially to Hepatosplenic T-cell Lymphoma (HTSCL) among Chron’s disease’s patients increased and received by the U.S. Food and Drug Administration (FDA), the agency warning to physician who prescribed this class of drug for that adverse effect that usually incurable.
As the HTSL incidences associated to this drugs, the FDA also warns several class of drugs of;
- infliximab, marketed as Remicade from Centocor,
- etanercept, marketed as Enbrel from Amgen and Pfizer,
- adlimumab, marketed as Humira from Abott Laboratories,
- certolizumab pegol, marketed as Cimzia from UCB,
- golimumab, marketed as Simponi from Centocor Ortho Biotech Inc, and
- immunosuppresive drugs of azathioprine and mercaptopurine.
The agency noted, “Although most reported cases of HTSCL occurred in patients treated with a comnination of medicines known to suppress the immune system, including the TNF blockers, azathioprine, and/or mercaptopurine, there have been cases reported in patients receiving azathioprine or mercaptopurine alone.”
Due to this, the FDA advised to healthcare professionals to evaluate and analyze carefully whether the benefits of these drugs to outweigh the risk, and discuss to patients and caregivers about its benefits and potential risks.
Related Posts:
Subscribe for latest health news via email
